{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=IBD&page=52",
    "query": {
      "condition": "IBD",
      "page": 52
    },
    "page_size": 10
  },
  "pagination": {
    "page": 52,
    "page_size": 10,
    "total_count": 1553,
    "total_pages": 156,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=IBD&page=53&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=IBD&page=51&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-26T20:08:50.572Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02757105",
      "title": "Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Irritable Bowel Syndrome With Diarrhea"
      ],
      "interventions": [
        {
          "name": "BEKINDA",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "RedHill Biopharma Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 127,
      "start_date": "2016-05-19",
      "completion_date": "2017-07-14",
      "has_results": true,
      "last_update_posted_date": "2018-08-28",
      "last_synced_at": "2026-10-26T20:08:50.572Z",
      "location_count": 16,
      "location_summary": "Huntsville, Alabama • Little Rock, Arkansas • North Little Rock, Arkansas + 12 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "North Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02757105"
    },
    {
      "nct_id": "NCT04723056",
      "title": "Zemedy Application for Irritable Bowel Syndrome",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "IBS - Irritable Bowel Syndrome"
      ],
      "interventions": [
        {
          "name": "Use of Zemedy Application",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2021-10-15",
      "completion_date": "2024-03-08",
      "has_results": true,
      "last_update_posted_date": "2025-05-28",
      "last_synced_at": "2026-10-26T20:08:50.572Z",
      "location_count": 1,
      "location_summary": "Redwood City, California",
      "locations": [
        {
          "city": "Redwood City",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04723056"
    },
    {
      "nct_id": "NCT02019602",
      "title": "A Multicener, Postmarketing Study Evaluating the Transfer of Cimzia From the Mother to the Infant Via the Placenta",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Axial Spondyloarthritis (AxSpA)",
        "Non-radiographic Evidence-AxSpA",
        "Ankylosing Spondylitis",
        "Crohn's Disease",
        "Psoriatic Arthritis",
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Blood sampling from mother",
          "type": "PROCEDURE"
        },
        {
          "name": "Blood sampling from infant",
          "type": "PROCEDURE"
        },
        {
          "name": "Blood sampling from umbilical cord",
          "type": "PROCEDURE"
        },
        {
          "name": "Certolizumab Pegol",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "UCB BIOSCIENCES, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 37,
      "start_date": "2014-01",
      "completion_date": "2016-11",
      "has_results": true,
      "last_update_posted_date": "2019-06-21",
      "last_synced_at": "2026-10-26T20:08:50.572Z",
      "location_count": 3,
      "location_summary": "Scottsdale, Arizona • Oklahoma City, Oklahoma • Salt Lake City, Utah",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02019602"
    },
    {
      "nct_id": "NCT02156557",
      "title": "Study of KCC Peptide Application in the Colon",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Colon Polyps",
        "Colorectal Cancer",
        "Inflammatory Bowel Disease (IBD)"
      ],
      "interventions": [
        {
          "name": "Colon KCC Heptapeptide",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Danielle Kim Turgeon",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 45,
      "start_date": "2014-06",
      "completion_date": "2016-08",
      "has_results": false,
      "last_update_posted_date": "2017-04-04",
      "last_synced_at": "2026-10-26T20:08:50.572Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02156557"
    },
    {
      "nct_id": "NCT07186101",
      "title": "LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ulcerative Colitis"
      ],
      "interventions": [
        {
          "name": "LY4268989",
          "type": "DRUG"
        },
        {
          "name": "Mirikizumab",
          "type": "DRUG"
        },
        {
          "name": "LY4268989 Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 252,
      "start_date": "2025-11-10",
      "completion_date": "2029-03",
      "has_results": false,
      "last_update_posted_date": "2026-10-08",
      "last_synced_at": "2026-10-26T20:08:50.572Z",
      "location_count": 40,
      "location_summary": "Scottsdale, Arizona • Anaheim, California • Lancaster, California + 36 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Lancaster",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07186101"
    },
    {
      "nct_id": "NCT07483099",
      "title": "A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Crohn Disease"
      ],
      "interventions": [
        {
          "name": "LY4395089",
          "type": "DRUG"
        },
        {
          "name": "Mirikizumab - Intravenous (IV)",
          "type": "DRUG"
        },
        {
          "name": "Mirikizumab - Subcutaneous (SC)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 60,
      "start_date": "2026-05-04",
      "completion_date": "2028-03",
      "has_results": false,
      "last_update_posted_date": "2026-10-08",
      "last_synced_at": "2026-10-26T20:08:50.572Z",
      "location_count": 14,
      "location_summary": "Scottsdale, Arizona • Los Angeles, California • Oxnard, California + 11 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oxnard",
          "state": "California"
        },
        {
          "city": "Englewood",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07483099"
    },
    {
      "nct_id": "NCT00652145",
      "title": "Dose Escalation and Remission (DEAR)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Ulcerative Colitis"
      ],
      "interventions": [
        {
          "name": "mesalamine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "James Lewis",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 119,
      "start_date": "2008-09",
      "completion_date": "2013-01",
      "has_results": true,
      "last_update_posted_date": "2015-05-05",
      "last_synced_at": "2026-10-26T20:08:50.572Z",
      "location_count": 8,
      "location_summary": "Naples, Florida • Winter Park, Florida • Atlanta, Georgia + 5 more",
      "locations": [
        {
          "city": "Naples",
          "state": "Florida"
        },
        {
          "city": "Winter Park",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Chevy Chase",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00652145"
    },
    {
      "nct_id": "NCT00771667",
      "title": "A Study of Safety and Effectiveness of Ustekinumab in Patients With Moderate to Severe Active Crohn's Disease Who Have Been Previously Treated With Anti-TNF Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Crohn's Disease"
      ],
      "interventions": [
        {
          "name": "Placebo (IP)",
          "type": "DRUG"
        },
        {
          "name": "Ustekinumab 1mg/kg (IP)",
          "type": "DRUG"
        },
        {
          "name": "Ustekinumab 3 mg/kg (IP)",
          "type": "DRUG"
        },
        {
          "name": "Ustekinumab 6 mg/kg (IP)",
          "type": "DRUG"
        },
        {
          "name": "Placebo IV - Responder - Placebo SC (MP)",
          "type": "DRUG"
        },
        {
          "name": "Placebo IV - Nonresponder - Ustekinumab 270/90 mg SC (MP)",
          "type": "DRUG"
        },
        {
          "name": "Ustekinumab IV - Responder - Placebo SC (MP)",
          "type": "DRUG"
        },
        {
          "name": "Ustekinumab IV - Responder - Ustekinumab 90mg SC (MP)",
          "type": "DRUG"
        },
        {
          "name": "Ustekinumab IV - Nonresponder - Placebo SC (MP)",
          "type": "DRUG"
        },
        {
          "name": "Ustekinumab IV - Nonresponder - Ustekinumab 90mg SC (MP)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Centocor, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 526,
      "start_date": "2008-12",
      "completion_date": "2010-12",
      "has_results": true,
      "last_update_posted_date": "2013-04-01",
      "last_synced_at": "2026-10-26T20:08:50.572Z",
      "location_count": 88,
      "location_summary": "Mobile, Alabama • Scottsdale, Arizona • La Jolla, California + 85 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Roseville",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00771667"
    },
    {
      "nct_id": "NCT03772145",
      "title": "Tofacitinib Response in Ulcerative Colitis - a Real World Prospective Multi-center Study",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Ulcerative Colitis"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 103,
      "start_date": "2018-11-27",
      "completion_date": "2024-01-29",
      "has_results": false,
      "last_update_posted_date": "2024-01-31",
      "last_synced_at": "2026-10-26T20:08:50.572Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03772145"
    },
    {
      "nct_id": "NCT01016262",
      "title": "Efficacy and Safety Study of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Proctitis, Ulcerative"
      ],
      "interventions": [
        {
          "name": "MAX-002",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Canasa®",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Forest Laboratories",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 119,
      "start_date": "2009-11-30",
      "completion_date": "2011-09-30",
      "has_results": true,
      "last_update_posted_date": "2019-08-28",
      "last_synced_at": "2026-10-26T20:08:50.572Z",
      "location_count": 22,
      "location_summary": "Birmingham, Alabama • Dothan, Alabama • Tucson, Arizona + 19 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Thornton",
          "state": "Colorado"
        },
        {
          "city": "Torrington",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01016262"
    }
  ]
}